Plain-English translation of NCT02354014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing bedaquiline, a medication that fights tuberculosis bacteria, in children and teenagers (newborns through age 17) who have drug-resistant tuberculosis. The medication will be given along with other standard tuberculosis drugs. Researchers want to understand how safe the medication is, how the body processes it, and how well it works to fight the infection.
Drug-resistant tuberculosis is very difficult to treat because the bacteria no longer responds to the most common medications. This trial exists to find out if this medication can help children and teenagers with this serious form of tuberculosis when combined with other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication by mouth in different doses depending on your age and weight. Younger children (under 12) take smaller doses, while older teenagers take larger doses. You would start with a higher dose for the first 2 weeks, then take a lower dose three times per week for the next 22 weeks. Throughout the trial, you would continue taking your other tuberculosis medications and have regular visits to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Mozambique
Philippines
Russia